Behrman Capital’s Acquisition of Orphan Reach

Goodwin Procter LLP advised Behrman Capital on the deal.

Behrman Capital announced the completion of its bolt-on acquisition of contract research organization Orphan Reach via its portfolio company, Emmes. Financial terms of the transaction were not disclosed.

Behrman Capital is a leading middle market private equity firm with a multi-decade history of investing in buyouts of growth companies in North America. The firm’s investments are focused in the defense and aerospace, healthcare services and specialty manufacturing and distribution sectors.

Orphan Reach is a leading Contract Research Organization serving the life sciences industry. The company aims to accelerate the clinical development of orphan drugs and facilitate patient access to urgently needed new treatments for rare conditions. 

Emmes is a global full service Contract Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation. The company has significant expertise in infectious diseases, vaccines, ophthalmology, oncology, neurology, substance use disorders, and maternal and child health.

The Goodwin team was led by Carl Bradshaw (Picture), Angus Simpson, Kit Bottomley and Luke Nauth and included Stuart Rosenthal, Sarah El-Ghazaly, Sindoori Sriram, Fred Lim, Nick Caro, Cary Chan, Robin Zhang, Simon Fulbrook, Richard Hughes, Robert Young, William Weiss and Kyle Pine.

Involved fees earner: Kit Bottomley – Goodwin Procter; Carl Bradshaw – Goodwin Procter; Nikolaus Caro – Goodwin Procter; Cary Chan – Goodwin Procter; Sarah El-Ghazaly – Goodwin Procter; Simon Fulbrook – Goodwin Procter; Richard Hughes – Goodwin Procter; Kyle Pine – Goodwin Procter; Fredrich Lim – Goodwin Procter; Stuart Rosenthal – Goodwin Procter; Angus Simpson – Goodwin Procter; Sindoori Sriram – Goodwin Procter; William Weiss – Goodwin Procter; Robert Young – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Behrman Capital;

Author: Federica Tiefenthaler